-
EP3883611
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3883611
| EP3883611 - USE OF IRE1ALPHA-XBP1 SIGNALING PATHWAY BIOMARKERS FOR MODULATING IMMUNE RESPONSES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 27.08.2021 Database last updated on 22.08.2024 | |
| Former | The international publication has been made Status updated on 30.05.2020 | Most recent event Tooltip | 27.11.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215-5450 / US | [2021/39] | Inventor(s) | 01 /
GLIMCHER, Laurie, H. 100 Beacon Street Unit 3A Boston, MA 02116 / US | 02 /
DONG, Han 170 Brookline Avenue, Unit 821 Boston, MA 02215 / US | [2021/39] | Representative(s) | Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE | [N/P] |
| Former [2021/39] | Helbig, Christian Wagner + Helbig Patentanwälte Pfarrstrasse 14 80538 München / DE | Application number, filing date | 19887898.5 | 11.11.2019 | [2021/39] | WO2019US60749 | Priority number, date | US201862769265P | 19.11.2018 Original published format: US 201862769265 P | US201962800706P | 04.02.2019 Original published format: US 201962800706 P | [2021/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020106483 | Date: | 28.05.2020 | Language: | EN | [2020/22] | Type: | A1 Application with search report | No.: | EP3883611 | Date: | 29.09.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.05.2020 takes the place of the publication of the European patent application. | [2021/39] | Search report(s) | International search report - published on: | US | 28.05.2020 | (Supplementary) European search report - dispatched on: | EP | 24.01.2023 | Classification | IPC: | C12N5/0783, A61P35/00, // A61K48/00, C12N15/00, C12Q1/68, G01N33/50 | [2023/08] | CPC: |
C12Q1/6886 (EP,US);
A61K2239/31 (EP,US);
A61K2239/38 (EP,US);
A61K2239/57 (EP,US);
A61K39/4613 (EP,US);
A61K39/4644 (EP,US);
A61K39/464838 (EP,US);
A61K45/06 (US);
A61P35/00 (EP,US);
C07K14/4705 (EP,US);
C12N15/111 (US);
C12N15/113 (US);
C12N5/0646 (EP,US);
C12N9/12 (EP);
C12Y207/11 (EP);
G01N33/5088 (EP);
C12N2501/2302 (EP);
C12N2501/2312 (EP);
C12N2501/2315 (EP);
C12N2501/2318 (EP);
C12N2501/998 (EP);
C12Q2600/106 (EP,US);
C12Q2600/158 (EP,US);
G01N2800/26 (EP);
G01N2800/7028 (EP)
(-)
|
| Former IPC [2021/39] | A61K48/00, A61P35/00, C12N5/071, C12N5/07, C12N15/00, C12Q1/68, G01N33/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/39] | Extension states | BA | 15.06.2021 | ME | 15.06.2021 | Title | German: | VERWENDUNG VON BIOMARKERN DES IRE1ALPHA-XBP1-SIGNALWEGS ZUR MODULATION VON IMMUNANTWORTEN | [2021/39] | English: | USE OF IRE1ALPHA-XBP1 SIGNALING PATHWAY BIOMARKERS FOR MODULATING IMMUNE RESPONSES | [2021/39] | French: | UTILISATION DE BIOMARQUEURS DE LA VOIE DE SIGNALISATION IRE1ALPHA-XBP1 POUR MODULER DES RÉPONSES IMMUNITAIRES | [2021/39] | Entry into regional phase | 15.06.2021 | National basic fee paid | 15.06.2021 | Search fee paid | 15.06.2021 | Designation fee(s) paid | 15.06.2021 | Examination fee paid | Examination procedure | 15.06.2021 | Examination requested [2021/39] | 21.08.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 29.11.2021 | Renewal fee patent year 03 | 28.11.2022 | Renewal fee patent year 04 | 27.11.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]US2012015841 (SHEKDAR KAMBIZ [US], et al); | [Y]US2013280269 (SAMALI AFSHIN [IE], et al); | [A]US2018298079 (LEFRANCOIS LEO [US], et al); |